Andere Sprachen Viridian Therapeutics, Inc.

Aktien

A2QMUH

US92790C1045

VRDN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
13,01 ^USD	+1,80 %		+3,50 %	-40,27 %

11.06.	Sektor-Update: Gesundheitstitel am Dienstag vorbörslich uneinheitlich	MT
11.06.	Sektor Update: Gesundheitswesen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Mixed Premarket Tuesday	11.06.
Sector Update: Health Care	11.06.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as US FOMC Meeting Begins	11.06.
Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket	11.06.
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease	11.06.
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-To-Severe Thyroid Eye Disease	11.06.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	07.06.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.06.
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences	31.05.
Viridian Therapeutics to Participate in Upcoming May Investor Conferences	13.05.
Viridian Therapeutics to Participate in Upcoming May Investor Conferences	10.05.
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Reports Q1 Revenue $72,000	08.05.
Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results	08.05.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	06.05.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03.05.
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024	29.04.
Foghorn Therapeutics Names Kristian Humer CFO	16.04.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04.04.
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm	29.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Viridian Therapeutics, Inc.

Aktien

A2QMUH

US92790C1045

VRDN

Andere Sprachen

Filter